Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to explain why he's buying the ...

We recently published a list of Billionaire George Soros Stock Portfolio: Top 10 Stock Picks. In this article, we are going ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

New York – The highly anticipated Best Places to Work World Rankings for 2024 have been revealed, showcasing 30 leading ...

Wang’s arrest represents a dramatic reversal of fortunes for AstraZeneca in China, where it is the largest foreign drugmaker by sales. Wang had been celebrated by state media for his contributions to ...

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...

The most recent trading session ended with Astrazeneca (AZN) standing at $66.26, reflecting a -0.39% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...